AOAC SPIFAN Stakeholder Panel Meeting Book (September 7, 2019)

Why to include the FDA materials now? • Difficult to find incurred samples with a certain level of MCPD/GE. • Further search will delay MLT Æ No AOAC OM Final action status to support regulatory compliance testing. • Procuring samples from other parts of the world (e.g. Russia) will take time and potential issues with customs.

Motion: Recommendation for SPIFAN to approve the sample set including 3 additional samples for the MLT on MCPD/GE.